FDA Seeks Input on Safer Fish Processing Rules
Published Date: 2/19/2026
Notice
Summary
The FDA wants your thoughts on how they collect info about safely processing and importing fish and seafood. This affects businesses that handle fish products, aiming to keep seafood safe and clean. You’ve got until April 20, 2026, to share your comments—no fees, just your voice helping shape safer seafood rules!
Analyzed Economic Effects
4 provisions identified: 1 benefits, 3 costs, 0 mixed.
Estimated 1.93M annual recordkeeping hours
FDA estimates the annual recordkeeping burden for part 123 at 1,930,264 total hours. Major line items include 1,260,000 hours for documenting monitoring of critical control points, 420,000 hours for sanitation records, 70,500 hours for calibration and testing records, and 65,600 hours for import verification records.
Seafood processors must keep HACCP records
If you operate a seafood processing business, you must collect and keep HACCP records under 21 CFR part 123. Records include monitoring values (times, temperatures, acidity), corrective actions, calibration, and sanitation logs, and they are normally reviewed at the end of a production lot, day, or week to verify control limits.
Importers must verify and document compliance
If you import fish or fishery products, Sec. 123.12 requires you to take affirmative steps and maintain records verifying that imports were processed in accordance with HACCP and sanitation provisions, and make those records available for FDA review as provided in Sec. 123.12(c).
No capital or O&M costs claimed
FDA states there are no capital costs or operating and maintenance (O&M) costs associated with this information collection (OMB Control Number 0910-0354).
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16728, Gastroenterology-Urology Devices; Reclassification of Diagnostic Endoscopic Light Source Systems To Be Renamed Cystoscopic Systems Intended as an Aid for Detection of Bladder Cancer
The Food and Drug Administration (FDA) is proposing to reclassify diagnostic endoscopic light source systems (product code OAY), which are postamendments class III devices, from class III (premarket approval) into class II (special controls), subject to premarket notification. FDA is also proposing a new device classification regulation with the name "Cystoscopic system intended as an aid for detection of bladder cancer," along with special controls that FDA believes are necessary to provide a reasonable assurance of the safety and effectiveness of these devices.
2026-16712, Agency Information Collection Activities; Proposed Collection; Comment Request; Imports and Electronic Import Entries
The FDA wants your thoughts on how they collect info about imports and electronic import entries. If you’re involved in importing goods, this could affect you! They’re asking for comments by October 16, 2026, to help improve the process without adding extra costs or hassle.
2026-16727, Hematology and Pathology Devices; Reclassification of In Situ Hybridization Test Systems for Use With a Corresponding Approved Oncology Therapeutic Product
The Food and Drug Administration (FDA, the Agency, or we) is issuing a final order reclassifying in situ hybridization (ISH) test systems indicated for use with a corresponding approved oncology therapeutic product (product codes NYQ, MVD, OWE, and PNK), all postamendments class III (premarket approval) devices, into class II (special controls), subject to premarket notification. FDA is also establishing a new device classification regulation, along with the special controls that are necessary to provide a reasonable assurance of safety and effectiveness of this device type.
Previous / Next Documents
Previous: 2026-03310, Food and Drug Administration Modernization Act of 1997: Modifications to the List of Recognized Standards, Recognition List Number: 065
The FDA just updated its official list of standards that medical device makers can use to prove their products are safe and effective. These changes, effective February 19, 2026, help companies speed up the approval process by following clear, recognized rules. If you’re in the medical device world, this means smoother reviews and no surprise costs or delays!
Next: 2026-03312, Determination of Regulatory Review Period for Purposes of Patent Extension; SYMVESS
The FDA has set the official review period for SYMVESS, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind SYMVESS and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s diligence, you have until April 20 or August 18, 2026, to speak up—potentially impacting patent length and market exclusivity.